Citation Impact
Citing Papers
Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma
2008
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
2013
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
2015 StandoutNobel
Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802
2012
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
2010
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
2009 Standout
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients
2016
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
Autophagy in cancers including brain tumors: role of MicroRNAs
2020
Astrocytes: biology and pathology
2009 Standout
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
2007
IDH1andIDH2Mutations in Gliomas
2009 Standout
CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014
2017 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
The future of high-grade glioma: Where we are and where are we going
2015
Clinical development and potential of photothermal and photodynamic therapies for cancer
2020 Standout
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
2009
High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma
2010
Glioblastoma and Other Malignant Gliomas
2013 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Topographic maps in human frontal and parietal cortex
2009
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
2012
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
A 31-Year-Old Woman With a Transformed Low-grade Glioma
2010
Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme
2010
Autophagy in Brain Tumors: A New Target for Therapeutic Intervention
2011
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014 Standout
Controlled drug delivery vehicles for cancer treatment and their performance
2018 Standout
Consensus guidelines for diagnosis, prophylaxis and management of P neumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014
2014
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
2008 Standout
Human Posterior Parietal Cortex Flexibly Determines Reference Frames for Reaching Based on Sensory Context
2010
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
2010
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma
2008
The Future of Memory: Remembering, Imagining, and the Brain
2012 StandoutNobel
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA)
2009
Anaplastic Oligodendroglioma and Oligoastrocytoma
2007
Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas
2009
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
2013 Standout
Malignant Gliomas in Adults
2008 Standout
Resting state network estimation in individual subjects
2013
The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin
2007 Standout
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma
2017
A multi-modal parcellation of human cerebral cortex
2016 StandoutNature
Autophagy modulation as a potential therapeutic target for diverse diseases
2012 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors
2012
Sense of agency in the human brain
2017 Standout
A manifold of spatial maps in the brain
2010 StandoutNobel
Primary brain tumours in adults
2012 Standout
Default network activity, coupled with the frontoparietal control network, supports goal-directed cognition
2010
Functional Split between Parietal and Entorhinal Cortices in the Rat
2012 StandoutNobel
Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection
2015
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances
2006
Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy
2012 Standout
Diagnosis and Treatment of High-Grade Astrocytoma
2007
Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience
2013
Whatever next? Predictive brains, situated agents, and the future of cognitive science
2013 Standout
A Perivascular Niche for Brain Tumor Stem Cells
2007 Standout
Bevacizumab and daily temozolomide for recurrent glioblastoma
2011
Triadic (ecological, neural, cognitive) niche construction: a scenario of human brain evolution extrapolating tool use and language from the control of reaching actions
2011
Primary CNS Lymphoma in Immunocompetent Patients
2009
Management of glioblastoma: State of the art and future directions
2020 Standout
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015
2018 Standout
Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma
2007
A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme
2006
The modular and integrative functional architecture of the human brain
2015
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
2016 Standout
Semantic linking through spaces for cyber-physical-socio intelligence: A methodology
2011 Standout
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
2013 Standout
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
2008
The epidemiology of glioma in adults: a "state of the science" review
2014 Standout
Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision
2017 Standout
The Common Neural Basis of Autobiographical Memory, Prospection, Navigation, Theory of Mind, and the Default Mode: A Quantitative Meta-analysis
2008 Standout
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018
2021 Standout
MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
2008
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
2008 Standout
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016
2019 Standout
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
2007
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
2008
The Versatile Role of microRNA-30a in Human Cancer
2017 Standout
Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents
2006
Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma
2007
Stereotactic laser ablation of high-grade gliomas
2014
PCV chemotherapy for recurrent glioblastoma
2006
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
Lessons learned in the development of targeted therapy for malignant gliomas
2007
Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
2008
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
2010 Standout
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
2009
Epidemiologic and Molecular Prognostic Review of Glioblastoma
2014 Standout
An extent of resection threshold for newly diagnosed glioblastomas
2011 Standout
Local-Global Parcellation of the Human Cerebral Cortex from Intrinsic Functional Connectivity MRI
2017 Standout
Works of A. Tosoni being referenced
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
2007
Adjuvant chemotherapy in the treatment of high grade gliomas
2005
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
2009
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas
2008
O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications
2010
Sensory-motor mechanisms in human parietal cortex underlie arbitrary visual decisions
2008
Distinct representations for shifts of spatial attention and changes of reward contingencies in the human brain
2012
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
2006
Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma: Initial report of the EORTC study 26061
2008
Change in MGMT methylation status between first and second surgery for recurrence: Clinical implications
2009
Is protracted low-dose temozolomide feasible in glioma patients?
2006
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas
2006
Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group)
2004
Dynamic reorganization of human resting-state networks during visuospatial attention
2015
Gefitinib (ZD1839) treatment for adult patients with progressive high-grade gliomas (HGG): An open label, single-arm, phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
2005
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas
2004
EORTC Study 26041–22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma—Results of a phase I trial
2007
How effective is BCNU in recurrent glioblastoma in the modern era?
2004